Shield Therapeutics plc (STX)

Overview

Shield Therapeutics plc stands out in the specialty pharmaceutical sector with its core focus on developing and commercializing pharmaceuticals aimed at fulfilling unmet medical needs. Established in 2008 and headquartered in Gateshead, United Kingdom, the company has carved a niche in advancing clinical-stage treatments. Through its dedicated efforts, Shield Therapeutics plc has made significant strides in offering innovative therapeutic solutions to address challenging medical conditions, thereby contributing to the betterment of patient care worldwide.

Products and Services

• Accrufer/Feraccru
  

  This leading product of Shield Therapeutics plc is a groundbreaking, non-salt based oral therapy designed for the treatment of iron deficiency, with or without anemia, in adult patients. Its unique formulation allows for effective management of iron levels without the gastrointestinal side effects commonly associated with traditional iron salt therapies. Accrufer/Feraccru provides a crucial alternative for patients seeking an effective and tolerable treatment for iron deficiency.

• PT20
  

  PT20 represents an innovative approach to the management of hyperphosphatemia in individuals suffering from chronic kidney disease. Having successfully completed its Phase II pivotal study, PT20 is a novel iron-based phosphate binder that showcases Shield Therapeutics’ commitment to addressing complex medical challenges. This promising product has the potential to offer a new therapeutic option for patients managing the complications associated with chronic kidney disease.